雷尼基奥仑赛注射液 | China Drugs ListRanicabtagene autoleucel injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 上海恒润达生生物科技股份有限公司Shanghai Hrain Biotechnology Co., Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 本品用于治疗经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤，包括弥漫性大 B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的弥漫性大 B细胞淋巴瘤、伴MYC 和BCL2 重排的高级别 B细胞淋巴瘤、高级别 B细胞淋巴瘤非特指型。For adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic treatment, including diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma transformed from follicular lymphoma, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and high-grade B-cell lymphoma not otherwise specified.
- 适应症来源与口径
- 来源日期： 2025, 2026. 适应症反映所引用的历史批准范围，不是截至2026年的完整适应症。Source date(s): 2025, 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
- 说明书信息局限
- 尚未取得可核实的完整药品说明书。现有批准记录或国家医保局申报资料支持所示适应症；最新完整范围尚待确认。A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.